Kiin Bio, a British life sciences startup, has closed an oversubscribed €1.9 million pre-seed round to launch KiinOS, its AI-native Virtual Scientist Platform aimed at transforming drug discovery. The round was led by b2venture, with support from Heartfelt, rule30, and strategic angels.
CEO and co-founder Filippo Abbondanza said that the future of drug discovery lies in smart integration and the company’s platform turns fragmented tools into a unified engine for breakthroughs.
Built to streamline tasks from literature review to wet-lab execution, KiinOS combines agentic AI, bioinformatics, and scalable infrastructure. Already in pilot with partners via its Frontier Programme, Kiin Bio plans to expand its platform and team, with a community edition coming later this year.
Featured image: Credit: Kiin Bio
